Details
Description
In this report we examined counts of individuals who received Sinuva or Propel, both of which are mometasone furoate sinus stents, for the treatment of nasal polyps in the Sentinel Distributed Database (SDD). Additionally, we examined these individuals further on whether or not they also had a record indicating the presence of glaucoma or cataracts in the six months prior to receiving the Sinuva sinus stent.
We distributed this query to 14 Sentinel Data Partners on July 2, 2021. The study period includes data from January 1, 2016 through April 30, 2021.